There are several recorded cases of soft tissue injury (STI) suffered by active duty U.S. Army personnel. These kinds of low-extremity wounds—although not fatal—results in decreased physical activity and substantial medical costs. Especially, for active duty soldiers, STI delays their return to duty, and the prolonged recovery time often causes acute depression among the patriots. For the past few decades, therapeutic ultrasound has been used to help such soldiers repress the STI pain and heal faster. Despite its widespread use, the ultrasound machines are confined within the boundaries of health care centers. The lack of mobility of the therapy coupled with its limited dosage time more often than not causes delayed treatment, and hence puts a hefty financial and psychological burden on the patients. However, thanks to ZetrOz, a medical device manufacturing company from Connecticut, soldiers can now recover from soft-tissue injury 50 percent faster with the company’s proprietary wearable therapeutic ultrasound device, thus eliminating the need for regular visits to hospitals or clinics.
Founded in 2009, ZetrOz started its journey as a key manufacturer of wearable low-intensity ultrasound system, UltrOz, for the equestrian market to deliver sustained acoustic medicine (sam). Soon, with FDA approval ZetrOz released sam Sport—wearable ultrasound systems for athletes with STI and musculoskeletal pain. Following the success in the sporting arena, today, ZetrOZ Systems has developed sam Pro 2.0 for commercial use to treat arthritis and other degenerative conditions. At present, Sam is the only FDA-cleared, wearable low-intensity ultrasound device in the market.
Considering sam’s effectiveness in treating non-invasive soft tissue injuries, the U.S. Department of Veterans Affairs (VA) and the Department of Defense (DoD) have also approved sam to treat their armed forces.
Instead of consuming opiates or going for surgery, civilians, veterans, and active duty soldiers can use ZetrOz’s wearable therapeutic ultrasound—sam—for pain management and physical therapy
With the Government approval of wearable therapeutic ultrasound for its current and retired armed forces, ZetrOz marked its inception in the U.S. government space. “sam is now a part of VA and DoD’s standard healing procedure for STI. Instead of consuming opiates or going for surgery, civilians, veterans, and active duty soldiers can use ZetrOz’s wearable therapeutic ultrasound— sam—for pain management and physical therapy,” says Dwayne Hofstatter, chief innovation officer at ZetrOz.
ZetrOz’s family of sam products is capable of providing ultrasound therapy to a patient for up to three-four hours daily. Powered by a rechargeable battery, sam uses a miniaturized ultrasound device to deliver the low intensity-long duration mode of treatment, using 18 times more energy than clinical ultrasound therapy. Before releasing the product in the market, sam went through different levels of clinical verification and validation trials to ensure the product can be easily and successfully applied. The sam clinical study conducted across trial patients in the U.S. demonstrated a striking reduction in pain related to osteoarthritis and chronic tendinopathy. “At the same time, sam has also demonstrated its capability to improve the life quality of its patients,” boasts Hofstatter.
ZetrOZ Systems is now heavily investing in research and development to expand the capabilities of sam to find its usage in different patient demographics. To do so, ZetrOZ has entered into collaborative partnerships with more than 20 VA hospitals and clinics around the U.S. to make sam available to more civilians and government personnel. ZetrOz is also collaborating with U.S. DoD to extend the possibility of using sam to heal open wounds caused by burns and shrapnel, and speed-up post-surgery healing of the soldiers to prevent infection. Above all, ZetrOZ is joining forces with federal institutes and universities across the U.S. to develop new sam-based medical products and usher a new dimension in soft-tissue injury treatment.
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: